A study of a next generation mRNA-LNP vaccine against SARS-CoV-2

Submission date	Recruitment status	[X] Prospectively registered
28/11/2023	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
23/04/2024	Completed	Results
Last Edited	Condition category	Individual participant data
11/04/2025	Infections and Infestations	[X] Record updated in last year

Plain English summary of protocol

Background and study aims

This is a proof-of-platform trial of a new mRNA-Lipid Nanoparticle (LNP) vaccine against COVID-19. The test vaccine (NeomiVac) has been developed by NeoVac Ltd and is similar to other mRNA COVID-19 vaccines, but uses a new LNP formulation which has the potential to be stored at fridge temperature for longer than existing mRNA vaccines. This would make mRNA vaccines easier to use, ship, handle and store, especially for healthcare professionals in low- and middle-income countries. This first-in-human trial aims to test the safety and immune response of NeomiVac at three different doses. If shown to be safe and immunogenic, the mRNA molecule in the NeomiVac vaccine may be updated to tackle new COVID-19 variants of concern (as has been done for existing mRNA COVID-19 vaccines), whilst the same lipid nanoparticle formulation may also be used to develop new mRNA vaccines to protect against different infectious diseases.

Who can participate?

Healthy volunteers aged 18 to 64 years of age.

What does the study involve?

Participants will initially be screened for eligibility through an online questionnaire, followed by an in-person medical assessment by a trained clinician. Eligible participants will be assigned into three sequential cohorts.

- 1. Cohort 1 (6 participants): participants will receive a single low dose of NeomiVac (25 micrograms)
- 2. Cohort 2 (15 participants): participants will receive a single middle dose of NeomiVac (50 micrograms)
- 3. Cohort 3 (15 participants): participants will receive a single high dose of NeomiVac (100 micrograms)

All vaccinations will be administered via intramuscular injection. There will be safety reviews after the first and third participants in each cohort is vaccinated to confirm it is safe to vaccinate further participants at the tested dose. There will also be safety reviews once all participants in a cohort

have been vaccinated before proceeding to vaccinate the next cohort at a higher dose. Participants will be followed up for 6 months from vaccination. Blood samples will be taken at

D0 before vaccination and then at Day 3, Day 7, Day 14, Day 28, Day (3 months) and Day 180 (6 months). Blood samples will be tested for safety parameters at all timepoints and for immunogenicity at timepoints from Day 14 onwards.

What are the possible benefits and risks of participating?

By participating in this research, participants will help the research into the development of a novel platform vaccine against COVID-19 and potentially other diseases that the formulation is used to address. However, they will not directly receive any personal health benefit from the study or its procedures.

This is the first time that NeomiVac will be administered to humans and therefore the full risk profile of NeomiVac is not yet known. As with any vaccine, local adverse reactions are expected after intramuscular vaccination. These typically include pain, redness, swelling at the injection site, or underarm swelling or tenderness on the same side of the injection. Reactions are typically mild to moderate in severity, occurring within 24 hours of injection and resolving within 3 to 4 days of onset. Whilst NeomiVac has not previously been administered to humans, systemic adverse reactions have been observed for similar mRNA COVID-19 vaccines following vaccination, including headache, muscle pain, joint pain, fatigue, chills, nausea/vomiting and fatigue. These are usually mild to moderate in severity and in most cases they resolve spontaneously within several days. Participants will be able to reach the clinical team 24/7 in case of any concerns.

As with all injectable vaccines, immediate systemic allergic reactions to vaccination can occur. These reactions are very rare and are estimated to occur once per 450,000 vaccinations for vaccines that do not contain allergens such as gelatine or egg protein.

Where is the study run from? NeoVac Ltd. (UK)

When is the study starting and how long is it expected to run for? May 2024 to April 2025

Who is funding the study? NeoVac Ltd. (UK)

Who is the main contact? Vaccinetrials@ndm.ox.ac.uk

Contact information

Type(s)Scientific

Contact name

Dr Hannah Emami

Contact details

Unit 1&2 West 127 Olympic Avenue Milton Park Milton United Kingdom OX14 4SA +44 7500930091 clinicaltrials@neovac.co.uk

Type(s)

Principal investigator

Contact name

Dr Paola Cicconi

Contact details

CCVTM, University of Oxford, Churchill Hospital, Old Road, Headington Oxford United Kingdom OX3 7LE +44 1865 611425 paola.cicconi@ndm.ox.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

1006703

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

NeomiVac001, IRAS 1006703

Study information

Scientific Title

A phase I monotherapy study to evaluate the safety, tolerability and immunogenicity of a candidate next generation lipid nanoparticle (LNP) mRNA vaccine against SARS-CoV-2 (NeomiVac) in UK healthy adult volunteers

Study objectives

Primary Objective of the trial is to determine the safety and tolerability of different doses of a single vaccination of NeomiVac in healthy participants.

The Secondary Objectives are to assess the immune response to the vaccine

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 19/04/2024, South Central – Oxford A Research Ethics Committee (Temple Quay House, 2 The Square, Temple Quay, Bristol, BS1 6PN, United Kingdom; +44 207 104 8272; oxforda.rec@hra.nhs.uk), ref: 24/SC/0136

Study design

Interventional non randomized

Primary study design

Interventional

Study type(s)

Safety

Health condition(s) or problem(s) studied

COVID-19

Interventions

A total of 36 participants will take part in this open-label study. Each participant will be allocated to one of 3 treatment Cohorts in a sequential manner. All participants will receive a dose of NeomiVac and there is no placebo cohort.

Cohort 1: The first 6 eligible participants will receive a single low dose of NeomiVac (25 micrograms).

Cohort 2: The next 15 eligible participants will receive a single medium dose of NeomiVac (50 micrograms)

Cohort 3: The final 15 eligible participants will receive a single high dose of NeomiVac (100 micrograms).

All vaccinations will be administered via intramuscular injection. There will be safety reviews after the first and third participant in each cohort is vaccinated to confirm it is safe to vaccinate the remainder of the cohort at the tested dose. There will also be safety reviews 7 days after the last participant from each cohort is vaccinated before proceeding to the next cohort with a higher dose.

Intervention Type

Biological/Vaccine

Phase

Phase I

Drug/device/biological/vaccine name(s)

NeomiVac [mRNA]

Primary outcome(s)

Incidence of safety and reactogenicity events for approximately 6 months following the vaccination:

- 1. Adverse events and/or adverse events leading to study discontinuation
- 2. Serious adverse events
- 3. Grade ≥3 local and systemic reactions

Key secondary outcome(s))

Current secondary outcome measures as of 13/02/2025:

- 1. Binding IgG antibody levels to S protein to the Omicron variant and other relevant variants at baseline, D14, D28, D56 and D182
- 2. Neutralising antibody levels to Omicron and other relevant variants at baseline, peak antibody response as determined from IgG antibody levels and D182
- 3. Antigen-specific T cell responses to S antigen by IFN-gamma ELISPOT assays at baseline and at D14, D28, D56 and D182
- 4. Incidence of Grade ≥1 abnormalities in LFTs (ALT/AST/GGT) at baseline and at D3, D7, D14, D28, D56 and D182 timepoints

Previous secondary outcome measures:

- 1. Binding IgG antibody levels to S protein to the Omicron variant and relevant subvariants and to Wuhan at baseline, D14, D28, D56 and D182
- 2. Neutralising antibody levels to Omicron and Wuhan live virus (variants and relevant subvariants) at baseline, D14,D28, D56 and D182
- 3. Antigen-specific T cell responses to S antigen by IFN-gamma ELISPOT assays at baseline and at D14, D28, D56 and D182
- 4. Incidence of Grade ≥1 abnormalities in LFTs (ALT/AST/GGT) at baseline and at D3, D7, D14, D28, D56 and D182 timepoints

Completion date

30/04/2025

Eligibility

Key inclusion criteria

- 1. Healthy adults aged 18 to 64 years.
- 2. Able and willing (in the Investigator's opinion) to comply with all study requirements.
- 3. Willing to allow confirmation of their past medical history either through provision of a GP medical record summary, allowing investigators to obtain a copy of their medical history from their GP practice or by providing an alternative acceptable means of confirming their past medical history.
- 4. Agreement to refrain from blood donation during the course of the study.
- 5. Provide written informed consent.
- 6. For women of childbearing potential only: Willingness to practice continuous effective contraception for the duration of the trial.
- 7. For women of childbearing potential only: A negative pregnancy test on the day of both screening and vaccination.
- 8. Considered healthy with no current conditions that may significantly impair participant safety or influence study results, in the opinion of the Investigator.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Lower age limit

18 years

Upper age limit

64 years

Sex

All

Total final enrolment

36

Key exclusion criteria

- 1. A history of COVID-19 infection (confirmed either by lateral flow test or PCR) within 30 days of the study vaccination.
- 2. Participation in another research study involving receipt of an investigational product in the 90 days preceding enrolment or during the trial follow up period.
- 3. Receipt of any COVID vaccine during the 3 months prior to screening and planned receipt of another COVID vaccine for 3 months after receiving the trial vaccine.
- 4. Planned or actual receipt of any non-COVID vaccines administered within 14 days (before or after) enrolment EXCEPT for live vaccines, which must not be given within 30 days of the trial vaccine.
- 5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- 6. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) systemically active immunosuppressant medication within the past 6 months.
- 7. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- 8. History of allergy to polyethylene glycol (PEG)
- 9. History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
- 10. History of anaphylaxis in relation to vaccination.
- 11. History of myocarditis, pericarditis, or any active known heart disease.
- 12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- 13. History of serious psychiatric condition likely to affect participation in the study.
- 14. Ongoing or planned pregnancy or breastfeeding during the trial follow up period.
- 15. Bleeding disorder (e.g. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.
- 16. Detectable circulating hepatitis B surface antigen (HBsAg).
- 17. Seropositive for hepatitis C virus (antibodies to HCV).
- 18. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis.
- 19. Participant has any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results

Date of first enrolment

15/05/2024

Date of final enrolment

24/10/2024

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Jenner Institute Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)

Jenner Institute, Clinical Vaccine Trials CCVTM, Churchill Hospital Old Road, Headington Oxford
United Kingdom
OX3 7LE

Sponsor information

Organisation

NeoVac Ltd.

Funder(s)

Funder type

Industry

Funder Name

NeoVac Ltd.

Results and Publications

Individual participant data (IPD) sharing plan

Datasets generated during and/or analysed during this study are not expected to be made available due to the commercial sensitivity of the trial.

IPD sharing plan summary

Not expected to be made available